JP2008519794A5 - - Google Patents

Download PDF

Info

Publication number
JP2008519794A5
JP2008519794A5 JP2007540588A JP2007540588A JP2008519794A5 JP 2008519794 A5 JP2008519794 A5 JP 2008519794A5 JP 2007540588 A JP2007540588 A JP 2007540588A JP 2007540588 A JP2007540588 A JP 2007540588A JP 2008519794 A5 JP2008519794 A5 JP 2008519794A5
Authority
JP
Japan
Prior art keywords
pyrimidine
benzo
furo
chloro
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007540588A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008519794A (ja
Filing date
Publication date
Priority claimed from GB0424972A external-priority patent/GB0424972D0/en
Priority claimed from EP05022665A external-priority patent/EP1776982A1/en
Application filed filed Critical
Priority claimed from PCT/EP2005/012087 external-priority patent/WO2006050965A1/en
Publication of JP2008519794A publication Critical patent/JP2008519794A/ja
Publication of JP2008519794A5 publication Critical patent/JP2008519794A5/ja
Withdrawn legal-status Critical Current

Links

JP2007540588A 2004-11-11 2005-11-11 ピリミジン化合物 Withdrawn JP2008519794A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0424972A GB0424972D0 (en) 2004-11-11 2004-11-11 Pyrimidine compounds
EP05022665A EP1776982A1 (en) 2005-10-18 2005-10-18 Pyrimidine compounds as histamine modulators
PCT/EP2005/012087 WO2006050965A1 (en) 2004-11-11 2005-11-11 Pyrimidine compounds as histamine modulators

Publications (2)

Publication Number Publication Date
JP2008519794A JP2008519794A (ja) 2008-06-12
JP2008519794A5 true JP2008519794A5 (enExample) 2008-12-25

Family

ID=35658998

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007540588A Withdrawn JP2008519794A (ja) 2004-11-11 2005-11-11 ピリミジン化合物

Country Status (6)

Country Link
US (1) US20080269239A1 (enExample)
EP (1) EP1812113A1 (enExample)
JP (1) JP2008519794A (enExample)
AU (1) AU2005303893A1 (enExample)
CA (1) CA2586316A1 (enExample)
WO (1) WO2006050965A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200804550B (en) * 2005-11-09 2009-08-26 Combinatorx Inc Methods, compositions, and kits for the treatment of medical conditions
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
WO2007090854A1 (en) * 2006-02-10 2007-08-16 Cellzome (Uk) Ltd. Azetidine amino pyrimidine compounds for the treatment of inflammatory disorders
EP1860109A1 (en) * 2006-05-24 2007-11-28 Cellzome (UK) Ltd. Azetidine amino pyrimidine compounds for the treatment of inflammatory disorders
TWI436761B (zh) * 2006-06-19 2014-05-11 Otsuka Pharma Co Ltd 使用噻唑衍生物之方法
PE20080520A1 (es) * 2006-07-11 2008-06-13 Janssen Pharmaceutica Nv Derivados de benzofuro- y benzotienopirimidina como moduladores del receptor de histamina h4
US8735411B2 (en) 2006-10-02 2014-05-27 Abbvie Inc. Macrocyclic benzofused pyrimidine derivatives
US7985745B2 (en) 2006-10-02 2011-07-26 Abbott Laboratories Method for pain treatment
TW200924781A (en) 2007-09-14 2009-06-16 Janssen Pharmaceutica Nv Thieno- and furo-pyrimidine modulators of the histamine H4 receptor
PE20090978A1 (es) * 2007-10-30 2009-07-13 Palau Pharma Sa DERIVADOS DE FURO {3,2-d} PIRIMIDINA
AR069869A1 (es) * 2007-12-21 2010-02-24 Exelixis Inc Derivados de benzofuro[3,2-d]pirimidinas inhibidores de proteinquinasas,composiciones farmaceuticas que los comprenden y usos de los mismos en el tratamiento del cancer.
EP2077263A1 (en) * 2008-01-02 2009-07-08 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Quinazolines and related heterocyclic compounds and their therapeutic use
US8278313B2 (en) * 2008-03-11 2012-10-02 Abbott Laboratories Macrocyclic spiro pyrimidine derivatives
TW200951136A (en) * 2008-03-17 2009-12-16 Palau Pharma Sa Furo[3,2-d]pyrimidine derivatives
US8546410B2 (en) 2008-05-05 2013-10-01 Abbvie Inc. Heteroaryl-fused macrocyclic pyrimidine derivatives
PE20110061A1 (es) 2008-06-12 2011-01-31 Janssen Pharmaceutica Nv Derivados de diamino-piridina, pirimidina y piridazina como moduladores del receptor h4 de histamina
EP2201982A1 (en) 2008-12-24 2010-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Histamine H4 receptor antagonists for the treatment of vestibular disorders
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
AR080055A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1
ES2527849T3 (es) 2010-02-02 2015-01-30 Novartis Ag Derivados de ciclohexilamida como antagonistas del receptor de CRF
AU2011343712B2 (en) 2010-12-16 2015-09-17 Genentech, Inc. Tricyclic PI3k inhibitor compounds and methods of use
AR086554A1 (es) 2011-05-27 2014-01-08 Novartis Ag Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina
JP2015525202A (ja) 2012-05-03 2015-09-03 ノバルティス アーゲー グレリン受容体アゴニストとしての２，７−ジアザ−スピロ［４，５］デカ−７−イル誘導体のｌ−リンゴ酸塩およびその結晶形態
PL2858647T3 (pl) 2012-06-08 2018-10-31 Sensorion Inhibitory receptora h4 do leczenia szumów usznych
KR102332836B1 (ko) 2013-03-26 2021-12-01 가부시키가이샤 한도오따이 에네루기 켄큐쇼 발광 소자, 화합물, 유기 화합물, 디스플레이 모듈, 조명 모듈, 발광 장치, 표시 장치, 조명 장치 및 전자 기기
KR102287012B1 (ko) * 2014-05-28 2021-08-09 덕산네오룩스 주식회사 유기전기 소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치
CN108431010B (zh) 2015-12-25 2021-10-15 株式会社半导体能源研究所 化合物、发光元件、显示装置、电子设备及照明装置
BR112018072511A2 (pt) * 2016-05-09 2019-03-12 Biogaia Ab métodos para selecionar uma cepa bacteriana e para profilaxia, inibição e/ou tratamento de uma alergia, cepa, e, composição antialérgica
CN110073510B (zh) 2016-12-28 2022-07-19 株式会社半导体能源研究所 发光元件、有机化合物、发光装置、电子设备及照明装置
JP2019006763A (ja) 2017-06-22 2019-01-17 株式会社半導体エネルギー研究所 有機化合物、発光素子、発光装置、電子機器、および照明装置
CN113302194A (zh) * 2019-01-04 2021-08-24 贝尔布鲁克实验室有限责任公司 作为治疗剂的cGAS活性的抑制剂
WO2024055112A1 (en) * 2022-09-13 2024-03-21 Risen (Suzhou) Pharma Tech Co., Ltd. Bifunctional compounds and pharmaceutical uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755583A (en) * 1970-06-05 1973-08-28 Chas0!nhx
JPH06220059A (ja) * 1993-01-28 1994-08-09 Tanabe Seiyaku Co Ltd 縮合ピリミジン誘導体及びその製法
AU2002336273A1 (en) * 2001-03-09 2002-09-24 Ortho-Mcneil Pharmaceutical, Inc. Heterocyclic compounds and their use as histamine h4 ligands.
JP4596915B2 (ja) * 2002-09-06 2010-12-15 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ チエノピロリルおよびフラノピロリル化合物並びにヒスタミンｈ４受容体リガンドとしてのそれらの使用
ES2344007T3 (es) * 2003-10-14 2010-08-16 The Arizona Board Of Regents On Behalf Of The University Of Arizona Inhibidores proteina quinasa.

Similar Documents

Publication Publication Date Title
HRP20201539T1 (hr) Pozitivni alosterni modulatori muskarinskog m1 receptora
JP2005508932A5 (enExample)
HRP20151250T1 (hr) Derivati izoksazolo-piridina
HRP20160036T1 (hr) Određeni kemijski entiteti, priprave i metode koji sadrže imidazopirimidin
JP2013515729A5 (enExample)
JP2010523556A5 (enExample)
CN106573006A (zh) 作为药物的rip1激酶抑制剂杂环酰胺
JP2011521963A5 (enExample)
HRP20161708T1 (hr) Supstituirani 4-fenil-piridini za terapiju bolesti povezanih sa nk-1 receptorom
JP2014505735A5 (enExample)
JP2011500621A5 (enExample)
JP2005516067A5 (enExample)
EA201401150A1 (ru) Аминоиндолилзамещенные имидазолпиримидины и их применение в качестве лекарственных средств
HRP20140599T1 (hr) Derivati kiinazolin-4(3h)-ona koji se koriste kao inhibitori pi3 kinaze
JP2009510044A5 (enExample)
JP2015522018A5 (enExample)
JP2016503785A5 (enExample)
JP2008519794A (ja) ピリミジン化合物
JP2015512888A5 (enExample)
JP2016028076A5 (enExample)
JP2019505529A5 (enExample)
JP2017526724A5 (enExample)
JP2013507426A5 (enExample)
AU2023222397A1 (en) Therapeutic phenethylamine compositions and methods of use
Roberts et al. 4-Amino-7, 8-dihydro-1, 6-naphthyridin-5 (6 H)-ones as inhaled phosphodiesterase type 4 (PDE4) inhibitors: structural biology and structure–activity relationships